Private Equity and Venture Capital Investment in the Global Pharmaceutical and Biotechnology Industry

Vigilance and Equanimity are the Needs of the Hour

Regular Price: USD 4,950

Special Price USD 4,455

10% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,455

PAY BY INVOICE

Be the first to review this product

This study for the private equity and venture capital trends in the global pharmaceutical and biotechnology industry analyzes the various deals in the industry. The deals are analyzed based on number and average value. The trends are also observed based on the geographic region and buyer types. The study delves into the nature of cross border deals and also keeps into account various deal multiples such as deal value and investment rounds. The distribution of deals across key therapeutic areas has been dealt to understand the focus of investors and to highlight the key therapeutic areas in the near future. The analysis also includes geography-wise interest of buyers in regions across other geographies in terms both deal value and volume.

Table of Contents

Executive SummaryExecutive SummaryKey Terms Used in the StudyKey Terms Used in the StudyKey Terms Used in the Study (continued)IntroductionObjectives of the StudyResearch Objective and ScopeResearch Objective and Scope (continued)Research MethodologyKey Trends in the Pharma and Biotech IndustryPharma and Biotech Industry—Stock Indices PerformanceReducing ProfitabilityRegulatory ChallengesPatent ExpiryChanging Role of Big PharmaKey PEVC StatisticsOverall HC Industry—PEVC Deal Trends by VolumePEVC Deal Trends by Volume and ValuePEVC Deal Trends by Average Deal Value by Transaction TypeVolume and Value of PE Deal Trends by SectorsPEVC Deals Involving Big PharmaVC Deals—Key MetricsVC Deal Trends by SectorsPharmaceutical Sector—Stages of VC Investment SnapshotPharmaceutical Sector—Stages of VC Investment Average Deal Value AnalysisBiotechnology Sector—Stages of VC Investment SnapshotBiotechnology Sector—Stages of Financing Deal Value AnalysisDeal Value Range AnalysisDeal Value Range Analysis—VC InvestmentDeal Value Range Analysis—PE InvestmentGeographic AnalysisPEVC Deal Analysis Across GeographiesPEVC Deal Share Analysis Across GeographiesPEVC Deal Analysis in the North American RegionPEVC Deal Snapshot in the North American RegionPEVC Deal Analysis in the European RegionPEVC Deal Snapshot in European RegionPEVC Deal Analysis in the APAC RegionPEVC Deal Snapshot in APAC RegionAnalysis of the Exit Market Volume Analysis of IPOValue Analysis of IPOValue Analysis of IPO by GeographyAnalysis of Deals Based on Key Therapeutic AreasPEVC Volume Analysis by Key Therapeutic AreasPEVC Value Analysis by Key Therapeutic AreasConclusionFive Big ConclusionsLegal DisclaimerThe Frost & Sullivan StoryWho is Frost & SullivanWhat Makes Us UniqueTEAM MethodologyOur Global Footprint 40+ Offices




Related Research

Release Date : 24-Jan-17

Region : Asia Pacific

Release Date : 12-Jul-2016

Region : Asia Pacific

Release Date : 31-May-2016

Region : Asia Pacific

Release Date : 11-May-16

Region : Asia Pacific

Release Date : 6-May-2016

Region : Asia Pacific

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.